LiteVax develop and exploit unique adjuvant platforms of fully synthetic compounds with distinct immunomodulatory profiles. Carbohydrates derivatives open opportunities for single-shot vaccines while heteropolymers are highly effective for booster immunization and mucosal application. These molecules are developed exclusively for its use as vaccine adjuvant and are the outcome of extensive optimization of efficacy/toxicity-ratio in large, non-rodent species.

Our most advanced product is a synthetic carbohydrate fatty acid monosulphate derivative (‘CMS’) immobilized on nano-droplets of a squalane-in-water emulsion. It elicits unprecedentedly high immune responses with no detectable local or systemic adverse reactions in animals. It is a third generation of chemically-defined carbohydrate-based adjuvants with further improved safety while retaining high efficacy.